A detailed history of Price T Rowe Associates Inc transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 63,109 shares of AVXL stock, worth $574,922. This represents 0.0% of its overall portfolio holdings.

Number of Shares
63,109
Previous 53,795 17.31%
Holding current value
$574,922
Previous $228,000 57.46%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$4.11 - $7.04 $38,280 - $65,570
9,314 Added 17.31%
63,109 $359,000
Q2 2024

Aug 14, 2024

BUY
$3.39 - $5.02 $6,851 - $10,145
2,021 Added 3.9%
53,795 $228,000
Q1 2024

May 15, 2024

BUY
$4.55 - $6.75 $4,304 - $6,385
946 Added 1.86%
51,774 $264,000
Q4 2023

Feb 14, 2024

BUY
$5.04 - $9.95 $6,647 - $13,124
1,319 Added 2.66%
50,828 $474,000
Q3 2023

Nov 14, 2023

BUY
$6.55 - $9.37 $40,217 - $57,531
6,140 Added 14.16%
49,509 $325,000
Q2 2023

Aug 14, 2023

BUY
$7.66 - $9.5 $6,702 - $8,312
875 Added 2.06%
43,369 $353,000
Q1 2023

May 15, 2023

BUY
$8.32 - $11.75 $3,552 - $5,017
427 Added 1.02%
42,494 $365,000
Q4 2022

Feb 14, 2023

BUY
$7.65 - $14.43 $4,788 - $9,033
626 Added 1.51%
42,067 $390,000
Q3 2022

Nov 14, 2022

BUY
$8.9 - $12.86 $39,872 - $57,612
4,480 Added 12.12%
41,441 $428,000
Q2 2022

Aug 15, 2022

BUY
$7.31 - $12.84 $3,720 - $6,535
509 Added 1.4%
36,961 $370,000
Q1 2022

May 16, 2022

BUY
$9.74 - $17.69 $46,235 - $83,974
4,747 Added 14.97%
36,452 $449,000
Q4 2021

Feb 14, 2022

BUY
$16.88 - $23.31 $11,208 - $15,477
664 Added 2.14%
31,705 $550,000
Q3 2021

Nov 15, 2021

BUY
$16.82 - $25.75 $166,518 - $254,925
9,900 Added 46.83%
31,041 $557,000
Q2 2021

Aug 16, 2021

SELL
$10.16 - $28.86 $5,090 - $14,458
-501 Reduced 2.31%
21,141 $483,000
Q1 2021

May 17, 2021

SELL
$5.17 - $16.13 $229,289 - $715,365
-44,350 Reduced 67.21%
21,642 $324,000
Q4 2020

Feb 16, 2021

BUY
$4.01 - $7.58 $264,627 - $500,219
65,992 New
65,992 $356,000

Others Institutions Holding AVXL

About ANAVEX LIFE SCIENCES CORP.


  • Ticker AVXL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,942,800
  • Market Cap $710M
  • Description
  • Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...
More about AVXL
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.